Vivo Bio Tech Reports Mixed Financial Results with Strong Profit Growth and Declining Margins in March 2025

Vivo Bio Tech, a microcap company in the Pharmaceuticals & Biotechnology sector, has released its financial results for the quarter ending March 2025. The evaluation changes indicate a notable shift in the company's score, which has adjusted to 5 from 10 over the past three months. The financial data reveals some positive trends for Vivo Bio Tech. The Profit After Tax (PAT) for the nine-month period stands at Rs 7.11 crore, reflecting a significant year-on-year growth of 197.49%. This upward trend in PAT is a strong indicator of the company's financial health. Additionally, net sales for the quarter reached Rs 12.29 crore, marking the highest figure in the last five quarters, suggesting a favorable near-term sales trajectory. However, not all aspects are performing well. The operating profit margin has reached its lowest point in the last five quarters at 40.85%, indicating a decline in the company's operational efficiency. Overall, Vivo Bio Tech's recent financial results highlight a mix of positive growth in profitability and sales, alongside challenges in operational efficiency. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.